Stock Splits
By The Online Investor Staff, updated Mon., Oct. 3, 2:51 PM
| This Slide: #6 of 25 |
Slide #6. Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) — 1 for 14 Reverse Split
Announced:
9/16/2022
Stock Split:
1 for 14
Record Date:
9/16/2022
Pay Date:
9/19/2022
SONN Optionable?:
No
Sonnet BioTherapeutics Holdings is a clinical-stage biopharmaceutical company with a proprietary technology for developing biologic medicines it refers to as FHAB (Fully Human Albumin Binding). Co. has a pipeline of therapeutic compounds focused primarily on oncology indications of unmet medical need, including SON-080, a low-dose formulation of Interleukin 6 which is in development for Chemotherapy Induced Peripheral Neuropathy; SON-1010, which is being developed for solid tumor indications, including non-small cell lung cancer and head and neck cancer, as well as for antiviral applications; and SON-1210, which is being developed for solid tumor indications, including colorectal cancer. 
SONN Detailed Information Page & Split History »
|
|||||||||||||||||||||
Open the SONN Page at The Online Investor (in a new window) »
 Free SONN Email Alerts:
Get SEC Filing Alerts Get Dividend Alerts 
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 74th percentile
(ranked higher than approx. 74% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
